Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Kenichiro Uemura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0003-6268; OpenAlex author ID A5078155870. Sources: OpenAlex.

Their work

Papers
68 (first author 28, last author 0)
Trials
0
Grants
0
Labs led
1
Collaborators
146
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: 5 papers · 2016: 6 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 8 papers · 2022: 11 papers · 2023: 6 papers · 2024: 5 papers · 2025: 3 papers · 2026: 11 papers

Papers 50 of 68

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. First author DOI 10.1002/jhbp.70113↗
  4. Reply to the Letter to the Editor Regarding "Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer… Co-author DOI 10.1002/jhbp.70202↗
  5. Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan. Co-author DOI 10.1007/s00535-025-02340-x↗
  6. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  7. Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Co-author DOI 10.1007/s12328-026-02388-z↗
  8. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  9. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  10. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-026-20710-4↗
  11. ASO Author Reflections: Assessment of Malignant Potential in Initially Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma by Combining CA19-9 and D… First author DOI 10.1245/s10434-026-20761-7↗
  12. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12898↗
  13. A type of pancreatic cancer cells form cell clusters from a solitary condition in a primary ciliogenesis-dependent manner. Co-author DOI 10.1007/s00795-025-00428-0↗
  14. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  15. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  16. Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemothera… Co-author DOI 10.1007/s00595-024-02824-y↗
  17. Δ3-tubulin impairs mitotic spindle morphology and increases nuclear size in pancreatic cancer cells. First author DOI 10.1007/s00795-023-00373-w↗
  18. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-024-15221-z↗
  19. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level. First author DOI 10.1245/s10434-024-15272-2↗
  20. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00423-023-03009-w↗
  21. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. First author DOI 10.1007/s00423-023-03073-2↗
  22. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  23. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… First author DOI 10.1007/s12328-022-01741-2↗
  24. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2023.10.019↗
  25. Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12196245↗
  26. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… First author DOI 10.1002/jhbp.1151↗
  27. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. First author DOI 10.1007/s00423-021-02339-x↗
  28. Case-control study of the correlation between the five times sit to stand and 6-min walk distance in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-022-07402-x↗
  29. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… First author DOI 10.1007/s12328-022-01621-9↗
  30. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. First author DOI 10.1016/j.pan.2021.12.009↗
  31. Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.02.001↗
  32. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … First author DOI 10.1016/j.pan.2022.03.018↗
  33. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. First author DOI 10.1016/j.pan.2022.04.004↗
  34. Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. First author DOI 10.1016/j.surg.2022.09.002↗
  35. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  36. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  37. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. First author DOI 10.1007/s00423-020-02025-4↗
  38. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. First author DOI 10.1007/s11605-021-04978-3↗
  39. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… First author DOI 10.1016/j.ejca.2021.10.012↗
  40. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. First author DOI 10.1016/j.pan.2021.01.022↗
  41. Changes in motor function and quality of life after surgery in patients with pancreatic cancer. Co-author DOI 10.1111/ecc.13368↗
  42. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. First author DOI 10.1159/000520064↗
  43. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-020-09278-9↗
  44. ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients. First author DOI 10.1245/s10434-020-09317-5↗
  45. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. First author DOI 10.1002/jhbp.687↗
  46. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Co-author DOI 10.1002/jhbp.737↗
  47. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Co-author DOI 10.1007/s00423-020-01914-y↗
  48. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.08.019↗
  49. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  50. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗

Closest collaborators

The 25 strongest of 146 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenjiro Okada · 31 shared papers, 2018–2026 · strength 5.09
  2. Shin’ya Takahashi · 32 shared papers, 2016–2026 · strength 5.06
  3. Tatsuaki Sumiyoshi · 24 shared papers, 2020–2026 · strength 4.99
  4. Yoshiaki Murakami · 42 shared papers, 2011–2026 · strength 4.70
  5. Naru Kondo · 24 shared papers, 2011–2024 · strength 2.84
  6. Hiroyuki Otsuka · 17 shared papers, 2020–2023 · strength 2.44
  7. Ryuta Shintakuya · 11 shared papers, 2018–2026 · strength 2.24
  8. Sohei Satoi · 20 shared papers, 2015–2026 · strength 2.22
  9. Yasutaka Ishii · 12 shared papers, 2016–2026 · strength 2.05
  10. Michiaki Unno · 17 shared papers, 2015–2026 · strength 1.66
  11. Kenta Baba · 6 shared papers, 2023–2026 · strength 1.36
  12. Fuyuhiko Motoi · 15 shared papers, 2015–2026 · strength 1.30
  13. Satoshi Hirano · 7 shared papers, 2022–2026 · strength 1.27
  14. Masayuki Sho · 14 shared papers, 2015–2026 · strength 1.21
  15. Daisuke Hashimoto · 7 shared papers, 2022–2026 · strength 1.18
  16. Masamichi Mizuma · 9 shared papers, 2015–2026 · strength 1.13
  17. Takumi Harada · 5 shared papers, 2023–2026 · strength 1.11
  18. Takeshi Sudo · 7 shared papers, 2011–2026 · strength 0.98
  19. Kaoru Seo · 2 shared papers, 2026 · strength 0.93
  20. Hiroki Yamaue · 13 shared papers, 2015–2026 · strength 0.93
  21. Shiro Oka · 4 shared papers, 2023–2026 · strength 0.90
  22. Teiichi Sugiura · 4 shared papers, 2025–2026 · strength 0.83
  23. Juri Ikemoto · 4 shared papers, 2022–2026 · strength 0.78
  24. Sho Tazuma · 3 shared papers, 2024–2026 · strength 0.76
  25. Ippei Matsumoto · 12 shared papers, 2015–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.